HCW Biologics, Inc. HCWB 深 沪
已收盘 07-02 16:00:00 美东时间
4.30
-0.280
-6.11%
华盛通- 最 高4.74
- 今 开4.49
- 成交量 10.21万股
- 最 低 4.22
- 昨 收 4.58
- 总市值 3079.29万
- 52周最高 44.10
- 市盈率 静 --
- 换手率 1.43%
- 52周最低 1.50
- 委 比 87.50%
- 总股本 716.12万
- 历史最高 1866.00
- 量 比 0.37
- 振 幅 11.35%
- 历史最低 1.50
- 每 手 1
- 风险率 9.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HCW Biologics Announces 1-For-6 Reverse Stock Split, Effective June 30
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseas...
06-26 20:56
Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss
HCW Biologics Inc. (NASDAQ:HCWB) stock fell during Tuesday’s session. The company announced preliminary results from its Phase 1 trial for HCW9302, an IL-2-based treatment for alopecia areata. All participants in the second-dose cohort showed clinical responses after a single dose of the treatment, ...
06-16 22:20
HCW Biologics Files Prospectus For Offering 5.69M Common Shares
https://www.sec.gov/Archives/edgar/data/1828673/000149315226027656/forms-1.htm
06-08 22:13
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
HCW Biologics Exercises Options To Regain Full Ex Vivo Rights HCW9206, HCW9201 From Wugen
HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today
05-27 19:47
HCW Biologics Prices Private Placement Of 2.84M Units At $1.405 Each
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-associated
05-21 21:56
What's Going On With HCW Biologics Stock Monday?
HCW Biologics (HCWB) reports Q1 EPS of $0.37 and $6.54M in sales. Find out why the stock skyrocketed and what's next.
05-18 19:14
Why Is HCW Biologics Stock Gaining Today?
HCW Biologics shares soared Friday after the company reported stronger quarterly results, advanced a key licensing deal and reaffirmed upcoming autoimmune clinical data milestones despite ongoing going-concern risks.
05-16 01:35
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Figma Inc (NYSE: FIG) shares rose 10.6% in pre-market trading after beating Q1 revenue and earnings estimates and raising FY26 sales guidance.
05-15 17:38
HCW Biologics Announces Its HCW11-040 Pembrolizumab-based Fusion Immunotherapeutic Discovered To Prevent Bronchopulmonary Dysplasia During IND-Enabling Trials
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and
05-14 19:35
